MAIN CONTENT
Orforglipron secures a first-mover advantage over injectable rivals
Prior to Thursday's clearance in Shanghai and Beijing, weight-management drugs in the GLP-1 class approved in China were restricted exclusively to injectable formulations. By bringing orforglipron to market first, Eli Lilly will compete for market share not only alongside its own once-weekly weight-loss injection, but also against injectable rivals from Novo Nordisk, Pfizer, and domestic Chinese biotech firm Innovent Biologics.
GLP-1 therapies work by mimicking a natural gut hormone to suppress appetite and regulate blood sugar levels. Eli Lilly has emphasized that an oral pill offers a compelling alternative for millions of prospective patients who dislike needles or face cold-chain storage hurdles.
Intensifying competition in the oral obesity drug pipeline
While Eli Lilly has claimed the opening slot, a crowded field of competitors is racing to bring oral weight-loss treatments to Chinese consumers. Novo Nordisk has already submitted an application to sell the pill version of its blockbuster Wegovy injection in China, joining domestic contenders developing experimental oral GLP-1 candidates such as Jiangsu Hengrui Pharmaceuticals and Huadong Medicine.















